PRESS RELEASE

Additional Patent Approvals for BiondVax around the World:
BiondVax Receives Approvals for Patent in Europe and Japan for its Universal Flu Vaccine

The patent approvals extend and strengthen BiondVax's intellectual property portfolio

Nes Ziona, Israel – October 29, 2014 – BiondVax Pharmaceuticals Ltd. (TASE: BNDX), which is developing the Universal Flu Vaccine, announced today that it received approvals from the European Union and from Japan's patent authorities for the Company's patent on the Multimeric Multi-Epitope Polypeptide Influenza Vaccines family. This is a family of patents for vaccination against influenza in humans, and specifically vaccines that confer a long-lasting protection against multiple flu strains. The patent approvals in Europe and Japan extend and strengthen BiondVax's intellectual property.

The newly-approved patent in Europe and Japan has already been approved in the US, , Hong Kong, Australia, China, Russia and Mexico. In addition, the Company is in the process for patent approval in Israel, where it may be completed soon.

Ron Babecoff, CEO of BiondVax said "We are excited on the dual patent approvals today: both in the EU and in Japan, which strengthen the acknowledgement for BiondVax around the world. The patent approval in Europe and Japan can set the ground and support the Company, if and as we work towards signing agreements with governments to use our unique technology."

About BiondVax Pharmaceuticals Ltd
BiondVax is a publicly traded (TASE: BNDX), advanced clinical stage biotech company dedicated to improving global protection against influenza, with its lead product a universal influenza (flu) vaccine called M-001. Influenza (flu) is a very common infectious disease, caused by countless flu strains as the virus mutates unpredictably and frequently. Current seasonal and pandemic flu vaccines are strain-specific and often mismatched to emerging flu strains. BiondVax's Universal Vaccine is meant to confer protection from most strains of seasonal and pandemic influenza by activating all parts of the immune system against conserved and common regions in most influenza virus strains.

Presently, BiondVax's universal flu vaccine (M-001) has several unique competitive advantages: the most advanced stage of clinical development according to information which is available to the company about its competitors (two phase 1/2 and two phase 2 clinical trials with 440 people); excellent safety profile; triggers both arms of our immune defenses; manufactured in only 6-8 weeks (conventional flu vaccines take 6-8 months) using a robust and standard method; unchanging composition enabling year-round production and stockpiling; and further, M-001 has two indications, as a standalone

universal flu vaccine and as a pandemic primer. This second indication when approved will provide pandemic preparedness AHEAD of flu outbreak as the prime-boost vaccination schedule can start immediately upon any pandemic declaration and will result in more people immunized.